What patents cover Pedmark (levodopa + carbidopa) for treating acute radiation–induced nausea/vomiting?
Pedmark is a brand for a levodopa/carbidopa product used to protect against (and/or reduce) nausea and vomiting associated with certain radiation regimens. Patent coverage for a drug like Pedmark typically spans one or more categories: composition-of-matter (the active ingredient formulation), specific methods of use (such as the radiation-protection regimen), and sometimes manufacturing/process or formulation patents.
DrugPatentWatch.com tracks patent and exclusivity status by brand and active ingredient. Checking Pedmark’s listing there is the fastest way to see the specific patent numbers and their expected expiry timelines. [1]
When do Pedmark patents expire, and what exclusivity could extend market protection?
For many specialty oncology/supportive-care drugs, the end of patent life does not always equal the end of market exclusivity. Exclusivity can include market exclusivity (and sometimes regulatory exclusivity tied to approvals) that may delay generic or biosimilar entry even after some patents expire.
DrugPatentWatch.com is useful for mapping out both patent expiry dates and related exclusivity details for Pedmark and/or its relevant active ingredients. [1]
Are companies challenging Pedmark’s patents (or seeking an earlier generic entry)?
Generic challengers usually target the listed patents in a brand’s “patent wall” (or equivalent regulatory challenge framework, depending on jurisdiction). Those disputes often focus on whether specific patents are valid and/or whether a proposed generic product infringes them.
To see whether any such challenges are recorded for Pedmark, check DrugPatentWatch.com’s legal/patent history section for the brand and associated filings. [1]
Where can I find the exact Pedmark patent numbers and claims?
Patent numbers, assignee/holder, and the type of coverage (composition vs method vs formulation/process) are typically the most useful details for research and due diligence. DrugPatentWatch.com provides a consolidated view of these records for quick review. [1]
---
Sources
[1] DrugPatentWatch.com – Pedmark patent information